Functional and Structural Imaging for Glaucoma
Oregon Health and Science University · with National Eye Institute (NEI) · NCT01957267
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 40–85 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 249
- US sites recruiting
- 1
- Study start
- September 25, 2013
- Record last updated
- September 9, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The specific aims of the clinical studies are to:
- Develop a directional high-resolution OCT and OCT angiography prototype to improve imaging of structure and perfusion.
- Validate wide-field OCT and OCT angiography parameters to improve early glaucoma detection.
- Simulate visual field results by combining structural and angiography OCT data.
- Assess abilities of above technologies and OCT-derived parameters on predicting glaucoma detection, conversion, and progression.
Conditions: Glaucoma
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria: Normal Subjects (both eyes must meet all criteria)
- No history or evidence of retinal pathology or glaucoma
- Normal Humphrey 24-2 VF: A mean defect (MD), corrected pattern standard deviation (CPSD) within 95% limits of normal reference, and glaucoma hemifield test (GHT) within normal limits (97%).
- Intraocular pressure \< 21 mm Hg
- Central corneal pachymetry > 500 microns
- No chronic ocular or systemic corticosteroid use
- Open angle (gonioscopy must show 75% or more of the angle to be Grade 2 or more by Shaffer's grading system)
- Normal appearing ONH and NFL: vertical and horizontal cup/disc ratio (CDR) ≤ 0.5 and intact neuroretinal rim without peripapillary hemorrhages, notches, localized pallor, or NFL defect
- Symmetric ONH between left and right eyes: CDR difference \< 0.2 in both vertical and horizontal dimensions
Inclusion criteria: Glaucoma Group
- ONH or NFL defect visible on slit-lamp biomicroscopy defined as one of following:
- diffuse or localized thinning of the rim
- disc (splinter) hemorrhage
- notch in the rim
- vertical cup/disc ratio greater than the fellow eye by > 0.2
- Presence or absence of VF defects as measured by Humphrey SITA 24-2 VF.
Exclusion Criteria: All Groups
- Best-corrected visual acuity less than 20/40
- Age \< 40 or >85 years
- Refractive error of > +3.00 D or \< -7.00 D
- Previous intraocular surgery except for uncomplicated keratorefractive surgery and cataract extraction with posterior chamber intraocular lens implantation
- Diabetic retinopathy
- Other diseases that may cause VF loss or optic disc abnormalities
- Inability to clinically view or photograph the optic discs due to media opacity or poorly dilating pupil
- Inability to perform reliably on automated VF testing
- Life-threatening or debilitating illness making it unlikely patient could successfully complete the study.
- Refusal of informed consent or of commitment to the full length of the study
Recruiting US locations
Oregon Health & Science University, Casey Eye Institute
Portland, OR 97214
Site contact: Chinmay Deshpande, M.Optom. · 503-494-9628 · deshpanc@ohsu.edu
Study contacts (from the official record)
- Chinmay Deshpande, M.Optom. · 503-494-9628 · deshpanc@ohsu.edu
- Denzil Romfh, OD · 503-494-4351 · romfhd@ohsu.edu
Similar studies in Oregon
All healthy volunteers studies in Oregon →- RecruitingHealthy volunteersPhase 1/Phase 2
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Novartis Pharmaceuticals
- Location
- Bend, OR + 18 other US sites
- Eligibility basics
- Ages 18–100
- RecruitingHealthy volunteersPhase 1/Phase 2
Immunogenicity of Yellow Fever Vaccine 17D in Adults With Prior 17D Vaccination
Oregon Health and Science University
- Location
- Portland, OR
- Eligibility basics
- Ages 20–49
- RecruitingHealthy volunteersEarly Phase 1
Monoferric for Prenatal Iron Deficiency
Oregon Health and Science University
- Location
- Portland, OR
- Eligibility basics
- Ages 18–65 · Women only
- RecruitingHealthy volunteersPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Portland, OR + 55 other US sites
- Eligibility basics
- Ages 18–79